Pancreatic cancer: Advances and challenges

Cites (302)

Items 201–301 of 301

1. Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer
   Parker, Seth J., Amendola, Caroline R., Hollinshead, Kate E.R., Yu, Qijia, Yamamoto, Keisuke, Encarnación-Rosado, Joel, Rose, Rebecca E., LaRue, Madeleine M., Sohn, Albert S.W., Biancur, Doug E. et al. · 2020 · Cancer Discovery
2. EGFR-Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis
   Lee, Szu-Wei, Zhang, Yijuan, Jung, Michael, Cruz, Nathalia, Alas, Basheer, Commisso, Cosimo · 2019 · Developmental Cell
3. Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia
   Shi, Guanglu, Zhu, Liqin, Sun, Yan, Bettencourt, Ryan, Damsz, Barbara, Hruban, Ralph H., Konieczny, Stephen F. · 2009 · Gastroenterology
4. The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma
   Krah, Nathan M, De La O, Jean-Paul, Swift, Galvin H, Hoang, Chinh Q, Willet, Spencer G, Chen Pan, Fong, Cash, Gabriela M, Bronner, Mary P, Wright, Christopher VE, MacDonald, Raymond J et al. · 2015 · eLife
5. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome
   Liudahl, Shannon M., Betts, Courtney B., Sivagnanam, Shamilene, Morales-Oyarvide, Vicente, da Silva, Annacarolina, Yuan, Chen, Hwang, Samuel, Grossblatt-Wait, Alison, Leis, Kenna R., Larson, William et al. · 2021 · Cancer Discovery
6. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia
   Shi, G, DiRenzo, D, Qu, C, Barney, D, Miley, D, Konieczny, S F · 2013 · Oncogene
7. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
   Luisa F. Escobar‐Hoyos, Alex Penson, Ram Kannan, Hana Cho, Chun‐Hao Pan, Rohit Kumar Singh, Lisa Helene Apken, G. Aaron Hobbs, Renhe Luo, Nicolas Lecomte et al. · 2020 · Cancer Cell
8. Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function
   Rajeshkumar, N.V., Dutta, Prasanta, Yabuuchi, Shinichi, de Wilde, Roeland F., Martinez, Gary V., Le, Anne, Kamphorst, Jurre J., Rabinowitz, Joshua D., Jain, Sanjay K., Hidalgo, Manuel et al. · 2015 · Cancer Research
9. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
   Margaret A. Tempero, Uwe Pelzer, Eileen Mary O'Reilly, Jordan Michael Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab et al. · 2022 · Journal of Clinical Oncology
10. Familial pancreatic cancer
    Petersen, Gloria M. · 2016 · Seminars in Oncology
11. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance
    Dalin, Simona, Sullivan, Mark R., Lau, Allison N., Grauman-Boss, Beatrice, Mueller, Helen S., Kreidl, Emanuel, Fenoglio, Silvia, Luengo, Alba, Lees, Jacqueline A., Vander Heiden, Matthew G. et al. · 2019 · Cancer Research
12. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation
    Roy, Nilotpal, Malik, Shivani, Villanueva, Karina E., Urano, Atsushi, Lu, Xinyuan, Von Figura, Guido, Seeley, E. Scott, Dawson, David W., Collisson, Eric A., Hebrok, Matthias · 2015 · Genes & Development
13. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells
    Bailey, J M, Hendley, A M, Lafaro, K J, Pruski, M A, Jones, N C, Alsina, J, Younes, M, Maitra, A, McAllister, F, Iacobuzio-Donahue, C A et al. · 2016 · Oncogene
14. Barriers and opportunities for gemcitabine in pancreatic cancer therapy
    Beutel, Alica K., Halbrook, Christopher J. · 2023 · American Journal of Physiology-Cell Physiology
15. Stromal cues regulate the pancreatic cancer epigenome and metabolome
    Sherman, Mara H., Yu, Ruth T., Tseng, Tiffany W., Sousa, Cristovao M., Liu, Sihao, Truitt, Morgan L., He, Nanhai, Ding, Ning, Liddle, Christopher, Atkins, Annette R. et al. · 2017 · Proceedings of the National Academy of Sciences
16. Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation
    von Figura, Guido, Morris, John P, Wright, Christopher V E, Hebrok, Matthias · 2014 · Gut
17. The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies
    Perez, Vincent M., Kearney, Joseph F., Yeh, Jen Jen · 2021 · Frontiers in Oncology
18. Clinical development of metabolic inhibitors for oncology
    Kathryn M. Lemberg, Sadakatali S. Gori, Takashi Tsukamoto, Rana Rais, Barbara S. Slusher · 2022 · Journal of Clinical Investigation
19. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
    Lee, Alex Y L, Dubois, Claire L, Sarai, Karnjit, Zarei, Soheila, Schaeffer, David F, Sander, Maike, Kopp, Janel L · 2019 · Gut
20. Discovery of 6-Diazo-5-oxo- l -norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma
    Rais, Rana, Jančařík, Andrej, Tenora, Lukáš, Nedelcovych, Michael, Alt, Jesse, Englert, Judson, Rojas, Camilo, Le, Anne, Elgogary, Amira, Tan, Jessica et al. · 2016 · Journal of Medicinal Chemistry
21. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia
    Catherine Carrière, E. Scott Seeley, Tobias Goetze, Daniel S. Longnecker, Murray Korc · 2007 · Proceedings of the National Academy of Sciences
22. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition
    George Sharbeen, Joshua A. McCarroll, Anouschka Akerman, Chantal Kopecky, Janet Youkhana, John Kokkinos, Jeff Holst, Cyrille Andre Boyer, Mert Erkan, David Goldstein et al. · 2021 · Cancer Research
23. MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice
    Collins, Meredith A., Yan, Wei, Sebolt–Leopold, Judith S., Pasca di Magliano, Marina · 2014 · Gastroenterology
24. The Impact of Neural Invasion Severity in Gastrointestinal Malignancies: A Clinicopathological Study
    Liebl, Florian, Demir, Ihsan Ekin, Mayer, Katharina, Schuster, Tibor, D'Haese, Jan G., Becker, Karen, Langer, Rupert, Bergmann, Frank, Wang, Kun, Rosenberg, Robert et al. · 2014 · Annals of Surgery
25. Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells
    Zhu, Xiphias Ge, Chudnovskiy, Aleksey, Baudrier, Lou, Prizer, Benjamin, Liu, Yuyang, Ostendorf, Benjamin N., Yamaguchi, Norihiro, Arab, Abolfozl, Tavora, Bernardo, Timson, Rebecca et al. · 2021 · Cell Metabolism
26. Elucidation of tumor-stromal heterogeneity and the ligand-receptor interactome by single-cell transcriptomics in Real-world pancreatic cancer biopsies
    Lee, Jaewon J., Bernard, Vincent, Semaan, Alexander, Monberg, Maria E., Huang, Jonathan, Stephens, Bret M., Lin, Daniel, Rajapakshe, Kimal I., Weston, Brian R., Bhutani, Manoop S. et al. · 2021 · Clinical Cancer Research
27. Early detection of pancreatic cancer using DNA-based molecular approaches
    Singhi, Aatur D., Wood, Laura D. · 2021 · Nature Reviews Gastroenterology & Hepatology
28. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
    Jiang, Honglin, Torphy, Robert J., Steiger, Katja, Hongo, Henry, Ritchie, Alexa J., Kriegsmann, Mark, Horst, David, Umetsu, Sarah E., Joseph, Nancy M., McGregor, Kimberly et al. · 2020 · Journal of Clinical Investigation
29. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials
    Javle, Milind, Shacham-Shmueli, Einat, Xiao, Lianchun, Varadhachary, Gauri, Halpern, Naama, Fogelman, David, Boursi, Ben, Uruba, Syeda, Margalit, Ofer, Wolff, Robert A. et al. · 2021 · JAMA Oncology
30. Machete identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis
    Barriga, Francisco M., Tsanov, Kaloyan M., Ho, Yu-Jui, Sohail, Noor, Zhang, Amy, Baslan, Timour, Wuest, Alexandra N., Del Priore, Isabella, Meškauskaitė, Brigita, Livshits, Geulah et al. · 2022 · Nature Cancer
31. Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin
    Elisa Espinet, Zuguang Gu, Charles David Imbusch, Nathalia A. Giese, Magdalena Büscher, Mariam Safavi, Silke Weisenburger, Corinna Klein, Vanessa Vogel, Mattia Falcone et al. · 2020 · Cancer Discovery
32. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
    de Wilde, Roeland F., Edil, Barish H., Hruban, Ralph H., Maitra, Anirban · 2012 · Nature Reviews Gastroenterology & Hepatology
33. Precancerous neoplastic cells can move through the pancreatic ductal system
    Makohon-Moore, Alvin P., Matsukuma, Karen, Zhang, Ming, Reiter, Johannes G., Gerold, Jeffrey M., Jiao, Yuchen, Sikkema, Lisa, Attiyeh, Marc A., Yachida, Shinichi, Sandone, Corinne et al. · 2018 · Nature
34. Inhibition of discoidin domain Receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma
    Aguilera, Kristina Y., Huang, Huocong, Du, Wenting, Hagopian, Moriah M., Wang, Zhen, Hinz, Stefan, Hwang, Tae Hyun, Wang, Huamin, Fleming, Jason B., Castrillon, Diego H. et al. · 2017 · Molecular Cancer Therapeutics
35. Cell of origin influences pancreatic cancer subtype
    Flowers, Brittany M., Xu, Hang, Mulligan, Abigail S., Hanson, Kathryn J., Seoane, Jose A., Vogel, Hannes, Curtis, Christina, Wood, Laura D., Attardi, Laura D. · 2021 · Cancer Discovery
36. Macropinocytosis in cancer-associated fibroblasts is dependent on CaMKK2/ARHGEF2 signaling and functions to support tumor and stromal cell fitness
    Zhang, Yijuan, Recouvreux, M. Victoria, Jung, Michael, Galenkamp, Koen M.O., Li, Yunbo, Zagnitko, Olga, Scott, David A., Lowy, Andrew M., Commisso, Cosimo · 2021 · Cancer Discovery
37. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
    Lander, Varintra E., Belle, Jad I., Kingston, Natalie L., Herndon, John M., Hogg, Graham D., Liu, Xiuting, Kang, Liang-I, Knolhoff, Brett L., Bogner, Savannah J., Baer, John M. et al. · 2022 · Cancer Discovery
38. Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma
    Cloyd, Jordan M., Wang, Huamin, Egger, Michael E., Tzeng, Ching-Wei D., Prakash, Laura R., Maitra, Anirban, Varadhachary, Gauri R., Shroff, Rachna, Javle, Milind, Fogelman, David et al. · 2017 · JAMA Surgery
39. Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma
    Garcia, Paloma E., Adoumie, Maeva, Kim, Esther C., Zhang, Yaqing, Scales, Michael K., El-Tawil, Yara S., Shaikh, Amara Z., Wen, Hui-Ju, Bednar, Filip, Allen, Ben L. et al. · 2020 · Cellular and Molecular Gastroenterology and Hepatology
40. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis
    Imamura, Takashi, Iguchi, Hiroshi, Manabe, Tadao, Ohshio, Gakuji, Yoshimura, Tsunehiro, Wang, Zhao-hui, Suwa, Hirofumi, Ishigami, Shunichi, Imamura, Masayuki · 1995 · Pancreas
41. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context
    Kerk, Samuel A, Lin, Lin, Myers, Amy L, Sutton, Damien J, Andren, Anthony, Sajjakulnukit, Peter, Zhang, Li, Zhang, Yaqing, Jiménez, Jennifer A, Nelson, Barbara S et al. · 2022 · eLife
42. Epithelial and stromal co-evolution and complicity in pancreatic cancer
    Hingorani, Sunil R. · 2023 · Nature Reviews Cancer
43. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
    Aatur Dilip Singhi, Siraj Mahamed Ali, Jill Lacy, Andrew Eugene Hendifar, Khanh Nguyen, Jamie Koo, Jon Chung, Joel R. Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova et al. · 2017 · Journal of the National Comprehensive Cancer Network
44. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
    Tsai, Yihsuan S., Woodcock, Mark G., Azam, Salma H., Thorne, Leigh B., Kanchi, Krishna L., Parker, Joel S., Vincent, Benjamin G., Pecot, Chad V. · 2022 · Journal of Clinical Investigation
45. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice
    Zhang, Yaqing, Yan, Wei, Mathew, Esha, Bednar, Filip, Wan, Shanshan, Collins, Meredith A., Evans, Rebecca A., Welling, Theodore H., Vonderheide, Robert H., di Magliano, Marina Pasca · 2014 · Cancer Immunology Research
46. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma
    Aguilera, Kristina Y., Rivera, Lee B., Hur, Hoon, Carbon, Juliet G., Toombs, Jason E., Goldstein, Courtney D., Dellinger, Michael T., Castrillon, Diego H., Brekken, Rolf A. · 2014 · Cancer Research
47. Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
    Qiu, Wanglong, Sahin, Fikret, Iacobuzio-Donahue, Christine A., Garcia-Carracedo, Dario, Wang, Wendy M., Kuo, Chia-Yu, Chen, Doris, Arking, Dan E., Lowy, Andrew M., Hruban, Ralph H. et al. · 2011 · Oncotarget
48. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis
    Flandez, Marta, Cendrowski, Jaroslaw, Cañamero, Marta, Salas, Antonio, del Pozo, Natalia, Schoonjans, Kristina, Real, Francisco X · 2014 · Gut
49. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial
    Bockorny, Bruno, Macarulla, Teresa, Semenisty, Valerya, Borazanci, Erkut, Feliu, Jaime, Ponz-Sarvise, Mariano, Abad, David Gutierrez, Oberstein, Paul, Alistar, Angela, Muñoz, Andres et al. · 2021 · Clinical Cancer Research
50. Hyaluronic acid fuels pancreatic cancer cell growth
    Kim, Peter K, Halbrook, Christopher J, Kerk, Samuel A, Radyk, Megan, Wisner, Stephanie, Kremer, Daniel M, Sajjakulnukit, Peter, Andren, Anthony, Hou, Sean W, Trivedi, Ayush et al. · 2021 · eLife
51. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene
    Hsu, Fang-Chi, Roberts, Nicholas J., Childs, Erica, Porter, Nancy, Rabe, Kari G., Borgida, Ayelet, Ukaegbu, Chinedu, Goggins, Michael G., Hruban, Ralph H., Zogopoulos, George et al. · 2021 · JAMA Oncology
52. Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
    Velez-Delgado, Ashley, Donahue, Katelyn L., Brown, Kristee L., Du, Wenting, Irizarry-Negron, Valerie, Menjivar, Rosa E., Lasse Opsahl, Emily L., Steele, Nina G., The, Stephanie, Lazarus, Jenny et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
53. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions
    Fujikura, Kohei, Hosoda, Waki, Felsenstein, Matthäus, Song, Qianqian, Reiter, Johannes G, Zheng, Lily, Beleva Guthrie, Violeta, Rincon, Natalia, Dal Molin, Marco, Dudley, Jonathan et al. · 2021 · Gut
54. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
    Pat Gulhati, Aislyn P. Schalck, Shan Jiang, Xiaoying Shang, Chang‐Jiun Wu, Pingping Hou, Sharia Hernández Ruiz, Luisa M. Solis Soto, Edwin Roger Parra, Haoqiang Ying et al. · 2022 · Nature Cancer
55. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
    Yi‐Hsuan Tsai, Mark G. Woodcock, Salma H. Azam, Leigh B. Thorne, Krishna Kanchi, Joel S. Parker, Benjamin Garrett Vincent, Chad Victor Pecot · 2022 · DOAJ (DOAJ: Directory of Open Access Journals)
56. Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer
    Schalck, Aislyn, Sakellariou-Thompson, Donastas, Forget, Marie-Andrée, Sei, Emi, Hughes, Tara G., Reuben, Alexandre, Bai, Shanshan, Hu, Min, Kumar, Tapsi, Hurd, Mark W. et al. · 2022 · Cancer Discovery
57. SWI/SNF component ARID1A restrains pancreatic neoplasia formation
    Wang, Sam C, Nassour, Ibrahim, Xiao, Shu, Zhang, Shuyuan, Luo, Xin, Lee, Jeon, Li, Lin, Sun, Xuxu, Nguyen, Liem H, Chuang, Jen-Chieh et al. · 2019 · Gut
58. Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice
    Perusina Lanfranca, Mirna, Zhang, Yaqing, Girgis, Alexander, Kasselman, Samantha, Lazarus, Jenny, Kryczek, Illona, Delrosario, Lawrence, Rhim, Andrew, Koneva, Lada, Sartor, Maureen et al. · 2020 · Gastroenterology
59. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells
    Halbrook, Christopher J., Thurston, Galloway, Boyer, Seth, Anaraki, Cecily, Jiménez, Jennifer A., McCarthy, Amy, Steele, Nina G., Kerk, Samuel A., Hong, Hanna S., Lin, Lin et al. · 2022 · Nature Cancer
60. Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer
    Ravichandran, Mirunalini, Hu, Jingjie, Cai, Charles, Ward, Nathan P., Venida, Anthony, Foakes, Callum, Kuljanin, Miljan, Yang, Annan, Hennessey, Connor J., Yang, Yang et al. · 2022 · Cancer Discovery
61. GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling
    Ideno, Noboru, Yamaguchi, Hiroshi, Ghosh, Bidyut, Gupta, Sonal, Okumura, Takashi, Steffen, Dana J., Fisher, Catherine G., Wood, Laura D., Singhi, Aatur D., Nakamura, Masafumi et al. · 2018 · Gastroenterology
62. Loss of Pten and activation of kras synergistically induce formation of intraductal papillary mucinous neoplasia from pancreatic ductal cells in mice
    Kopp, Janel L., Dubois, Claire L., Schaeffer, David F., Samani, Atefeh, Taghizadeh, Farnaz, Cowan, Robert W., Rhim, Andrew D., Stiles, Bangyan L., Valasek, Mark, Sander, Maike · 2018 · Gastroenterology
63. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
    Shaashua, Lee, Ben-Shmuel, Aviad, Pevsner-Fischer, Meirav, Friedman, Gil, Levi-Galibov, Oshrat, Nandakumar, Subhiksha, Barki, Debra, Nevo, Reinat, Brown, Lauren E., Zhang, Wenhan et al. · 2022 · Nature Communications
64. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer
    Kalisz, Mark, Bernardo, Edgar, Beucher, Anthony, Maestro, Miguel Angel, del Pozo, Natalia, Millán, Irene, Haeberle, Lena, Schlensog, Martin, Safi, Sami Alexander, Knoefel, Wolfram Trudo et al. · 2020 · The EMBO Journal
65. Spontaneous tumors, including gastrointestinal neoplasms and malignant melanomas, in the syrian hamster
    Joseph G. Fortner · 1957 · Cancer
66. T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor/mTORC2 protein for proliferative checkpoint decisions
    Van de Velde, Lee-Ann, Subramanian, Chitra, Smith, Amber M., Barron, Luke, Qualls, Joseph E., Neale, Geoffrey, Alfonso-Pecchio, Adolfo, Jackowski, Suzanne, Rock, Charles O., Wynn, Thomas A. et al. · 2017 · Journal of Biological Chemistry
67. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review
    Rahib, Lola, Fleshman, Julie M., Matrisian, Lynn M., Berlin, Jordan D. · 2016 · JAMA Oncology
68. Loss of Rnf43 accelerates kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma
    Hosein, Abdel Nasser, Dangol, Gita, Okumura, Takashi, Roszik, Jason, Rajapakshe, Kimal, Siemann, Megan, Zaid, Mohamed, Ghosh, Bidyut, Monberg, Maria, Guerrero, Paola A. et al. · 2022 · Gastroenterology
69. Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in patients with pancreatic cancer
    Peng, Hui, James, C. Alston, Cullinan, Darren R., Hogg, Graham D., Mudd, Jacqueline L., Zuo, Chong, Takchi, Rony, Caldwell, Katharine E., Liu, Jingxia, DeNardo, David G. et al. · 2021 · Clinical Cancer Research
70. Glutamine deprivation triggers NAGK-dependent hexosamine salvage
    Campbell, Sydney, Mesaros, Clementina, Izzo, Luke, Affronti, Hayley, Noji, Michael, Schaffer, Bethany E, Tsang, Tiffany, Sun, Kathryn, Trefely, Sophie, Kruijning, Salisa et al. · 2021 · eLife
71. ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models
    Nagashima, T., Inamura, K., Nishizono, Y., Suzuki, A., Tanaka, H., Yoshinari, T., Yamanaka, Y. · 2022 · European Journal of Cancer
72. Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress
    Hideo Tomihara, Federica Carbone, Luigi Perelli, Justin Kwang-Lay Huang, Melinda Soeung, Johnathon Lynn Rose, Frederick Scott Robinson, Yonathan Lissanu, Ningping Feng, Mitsunobu Takeda et al. · 2020 · Cancer Research
73. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway
    Boyer, Seth, Lee, Ho-Joon, Steele, Nina, Zhang, Li, Sajjakulnukit, Peter, Andren, Anthony, Ward, Matthew H, Singh, Rima, Basrur, Venkatesha, Zhang, Yaqing et al. · 2022 · eLife
74. PARP Inhibitors in Pancreatic Cancer
    Timothy J. Brown, Kim A. Reiss · 2021 · The Cancer Journal
75. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer
    Michail N. Mavros, Dimitrios Moris, Paul Jack Karanicolas, Matthew H. G. Katz, Eileen Mary O'Reilly, Timothy Michael Pawlik · 2021 · JAMA Surgery
76. Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth
    Sabin Kshattry, Achinto Saha, Paul Gries, Stefano Tiziani, Everett M Stone, George Georgiou, John DiGiovanni · 2019 · npj Precision Oncology
77. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma
    Lynch, Garrett, Kemeny, Nancy, Casper, Ephraim · 1982 · American Journal of Clinical Oncology
78. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
    DeNardo, David G, Galkin, Anna, Dupont, Jakob, Zhou, Lei, Bendell, Johanna · 2021 · Journal for ImmunoTherapy of Cancer
79. Arid1a restrains Kras-dependent changes in acinar cell identity
    Livshits, Geulah, Alonso-Curbelo, Direna, Morris, John P, Koche, Richard, Saborowski, Michael, Wilkinson, John Erby, Lowe, Scott W · 2018 · eLife
80. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
    Yan, Liang, Tu, Bo, Yao, Jun, Gong, Jing, Carugo, Alessandro, Bristow, Christopher A., Wang, Qiuyun, Zhu, Cihui, Dai, Bingbing, Kang, Ya'an et al. · 2021 · Cancer Research
81. Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes
    Momtaz, Parisa, O’Connor, Catherine A., Chou, Joanne F., Capanu, Marinela, Park, Wungki, Bandlamudi, Chaitanya, Berger, Michael F., Kelsen, David P., Suehnholz, Sarah P., Chakravarty, Debyani et al. · 2021 · Cancer
82. KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway
    Yi, Zhujun, Wei, Shanqiao, Jin, Lin, Jeyarajan, Sivakumar, Yang, Jing, Gu, Yumei, Kim, Hong Sun, Schechter, Shula, Lu, Shuang, Paulsen, Michelle T. et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
83. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice
    Kishimoto, Shun, Brender, Jeffrey R, Crooks, Daniel R, Matsumoto, Shingo, Seki, Tomohiro, Oshima, Nobu, Merkle, Hellmut, Lin, Penghui, Reed, Galen, Chen, Albert P et al. · 2019 · eLife
84. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
    James Thomas Topham, Erica S. Tsang, Joanna M. Karasinska, Andrew L. Metcalfe, Hassan Ali, Steve E. Kalloger, Veronika Csizmók, Laura Williamson, Emma Titmuss, Karina Nielsen et al. · 2022 · Nature Communications
85. NetrinG1(+) cancer-associated fibroblasts generate unique extracellular vesicles that support the survival of pancreatic cancer cells under nutritional stress
    Raghavan, Kristopher S., Francescone, Ralph, Franco-Barraza, Janusz, Gardiner, Jaye C., Vendramini-Costa, Débora B., Luong, Tiffany, Pourmandi, Narges, Andren, Anthony, Kurimchak, Alison, Ogier, Charline et al. · 2022 · Cancer Research Communications
86. Discoidin domain Receptor 1 (DDR1) is necessary for tissue homeostasis in pancreatic injury and pathogenesis of pancreatic ductal adenocarcinoma
    Ruggeri, Jeanine M., Franco-Barraza, Janusz, Sohail, Anjum, Zhang, Yaqing, Long, Daniel, Pasca di Magliano, Marina, Cukierman, Edna, Fridman, Rafael, Crawford, Howard C. · 2020 · The American Journal of Pathology
87. Molecular imaging of the tumor microenvironment reveals the relationship between tumor oxygenation, glucose uptake, and glycolysis in pancreatic ductal adenocarcinoma
    Yamamoto, Kazutoshi, Brender, Jeffrey R., Seki, Tomohiro, Kishimoto, Shun, Oshima, Nobu, Choudhuri, Rajani, Adler, Stephen S., Jagoda, Elaine M., Saito, Keita, Devasahayam, Nallathamby et al. · 2020 · Cancer Research
88. Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases
    Bechard, Matthew E., Word, Anna E., Tran, Amanda V., Liu, Xiaojing, Locasale, Jason W., McDonald, Oliver G. · 2018 · Oncogene
89. Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
    Park, Wungki, O'Connor, Catherine A., Bandlamudi, Chaitanya, Forman, Daniella, Chou, Joanne F., Umeda, Shigeaki, Reyngold, Marsha, Varghese, Anna M., Keane, Fergus, Balogun, Fiyinfolu et al. · 2022 · Clinical Cancer Research
90. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma
    Balachandran, Vinod P., Rojas, Luis A., Sethna, Zachary, Soares, Kevin, Derhovanessian, Evelyna, Mueller, Felicitas, Yadav, Mahesh, Basturk, Olca, Gonen, Mithat, Wei, Alice Chia-chi et al. · 2022 · Journal of Clinical Oncology
91. Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis
    Bechard, Matthew E., Smalling, Rana, Hayashi, Akimasa, Zhong, Yi, Word, Anna E., Campbell, Sydney L., Tran, Amanda V., Weiss, Vivian L., Iacobuzio-Donahue, Christine, Wellen, Kathryn E. et al. · 2020 · Nature Communications
92. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution
    Monberg, Maria E., Geiger, Heather, Lee, Jaewon J., Sharma, Roshan, Semaan, Alexander, Bernard, Vincent, Wong, Justin, Wang, Fang, Liang, Shaoheng, Swartzlander, Daniel B. et al. · 2022 · Nature Communications
93. Surveillance for neoplasia in the pancreas
    Overbeek, Kasper A., Cahen, Djuna L., Canto, Marcia Irene, Bruno, Marco J. · 2016 · Best Practice & Research Clinical Gastroenterology
94. Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives
    Holli Ann Loomans-Kropp, Asad Umar, Lori M. Minasian, Paul F. Pinsky · 2022 · Cancer Epidemiology Biomarkers & Prevention
95. Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
    Ferri-Borgogno, Sammy, Barui, Sugata, McGee, Amberly M., Griffiths, Tamara, Singh, Pankaj K., Piett, Cortt G., Ghosh, Bidyut, Bhattacharyya, Sanchari, Singhi, Aatur, Pradhan, Kith et al. · 2020 · Cancers
96. Differential Cell Susceptibilities to Kras in the Setting of Obstructive Chronic Pancreatitis
    Shi, Chanjuan, Pan, Fong Cheng, Kim, Jessica N., Washington, M. Kay, Padmanabhan, Chandrasekhar, Meyer, Christian T., Kopp, Janel L., Sander, Maike, Gannon, Maureen, Beauchamp, R. Daniel et al. · 2019 · Cellular and Molecular Gastroenterology and Hepatology
97. PASS-01: pancreatic adenocarcinoma signature stratification for treatment–01
    Knox, Jennifer J., Jaffee, Elizabeth M., O'Kane, Grainne M., Plenker, Dennis, Zhang, Amy, Ramotar, Stephanie, Dodd, Anna, Prince, Rebecca M., Laheru, Dan, Yu, Kenneth H. et al. · 2022 · Journal of Clinical Oncology
98. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN
    Liu, Ying, Kaur, Sukhwinder, Huang, Ying, Fahrmann, Johannes F., Rinaudo, Jo Ann, Hanash, Samir M., Batra, Surinder K., Singhi, Aatur D., Brand, Randall E., Maitra, Anirban et al. · 2020 · Cancer Epidemiology, Biomarkers & Prevention
99. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma
    Ecker, Brett L, Court, Colin M, Janssen, Quisette P, Tao, Alice J, D’Angelica, Michael I, Drebin, Jeffrey A, Gonen, Mithat, O’Reilly, Eileen M, Jarnagin, William R, Wei, Alice C et al. · 2022 · Journal of the American College of Surgeons
100. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?
     Thota, Ramya, Maitra, Anirban, Berlin, Jordan D. · 2017 · Pancreas
101. Precision Promise (PrP): an adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)
     Picozzi, Vincent J., Duliege, Anne-Marie, Collisson, Eric Andrew, Maitra, Anirban, Hidalgo, Manuel, Hendifar, Andrew Eugene, Beatty, Gregory Lawrence, Doss, Sudheer, Matrisian, Lynn McCormick, Herena, Pamela S et al. · 2022 · Journal of Clinical Oncology